



C19RM Monthly Update to the Board

24 JUNE 2021 | Geneva, Switzerland

Executive summary (1/2)

The COVID-19 pandemic remains a major global health crisis, **claiming a total of over 3.7 million lives to date**. While daily cases in some countries are decreasing, **models suggest infections far outnumber confirmed case numbers and emergence of new variants introduce new complexities in the countries we serve**.

While programmatic disruption shows some improvements, when compared to **2019 data and projections, data from 2020 shows the impact of COVID-19 on services to fight HIV, tuberculosis and malaria**. The number of new people initiated on ART is between **6% and ~12% less than expected**, there are between **10-50% fewer TB cases notified** and **10-16% fewer malaria cases tested**.

In 2020, C19RM **successfully deployed a total of US\$759 million**; US\$243 million (32%) for mitigating COVID-19's impact on HIV, TB and malaria programs; US\$442 million (58%) for reinforcing national COVID-19 responses; and US\$74 million (10%) for urgent improvements in health and community systems. **We expect to be able to report on the absorption (excluding grant flexibilities) of these investments later this year. Remaining C19RM 2020 funds are being integrated into C19RM 2021 awards to ensure holistic fund management.**

Leveraging the **lessons learned from 2020**, we have already enhanced C19RM 2021 with a focus **on increasing quality, effectiveness sustainability and downstream visibility**. We have also **improved risk management, assurance monitoring and oversight** especially for in country implementation activities and will continue to leverage these mechanisms to provide greater transparency to the Board and ensure **continuous improvement of our response**.

We have developed this monthly Board Report to cover the most relevant indicators based on the current state of our response. For this first edition in June, the report will **focus on the flow of funds, showing data on fast-track and early stages of the full funding awards**. As we move from awards into implementation, the focus of the report will shift and expand to more information on the flow of products and delivery of services in-country.

Executive summary (2/2)

As of 15 June 2021, C19RM has awarded or recommended US\$666 million for Board approval, including fast-track and full funding requests to 35 applicants. Given fast-track awards are to accelerate COVID-19 responses by providing urgently needed products, it is expected that nearly all awarded funds so far fit within the pillar of strengthening COVID-19 national responses (US\$585 million). As full funding requests come in, we expect other priority areas to expand.

Linked to WHO response pillars, the bulk of investments totaling US\$606 million has been awarded to the following pillars: laboratories (42%), case management (36%) and infection prevention (13%). The scope will likely broaden to include other pillars as more full funding requests are received.

On health products, 49% of awards are for oxygen provision so far, driven largely by India's fast-track funding request (US\$75 million, entirely for oxygen). Awards to other countries have been more evenly spread across diagnostics, personal protective equipment (PPE) and oxygen provision. While it is too early to discuss specific procurement insights, product demand data already shows largely unconstrained demand across all health products.

As we continue to improve C19RM, we have begun to identify challenges and improvement opportunities that will continue to inform our approach to the design and implementation of C19RM. Our due diligence approach includes cross Secretariat inputs, GAC/CTAG reviews and an Investment Committee review. We continue to look for ways to improve quality while maintaining urgency.

Going forward, we will continue to prioritize effective reporting from across the response and anticipate being able to share data on flow of products and services as it becomes available. In the next few weeks, we expect an additional 81 funding requests in windows 4 and 5 worth approximately US\$2.281 billion. We will seek to ensure that reports include information that will enable the Board to continue supporting and guiding our efforts to remain responsive to the needs of the diverse constituents we serve.

Outline and objective of the board report

This red box indicates that some numbers have been modified slightly from the original 24 June 2021 version that was shared with the Global Fund Board.

- **Key principles on monthly reporting to the Board**

- Report should deliver on the commitment to **increased transparency**, be responsive to queries, recommendations and inputs from Board meetings, papers and monthly reports, and others.
- Strategic focus of reporting should follow the flow of funds, products and services and information should be shared as it becomes available with an emphasis on **downstream visibility in relation to implementation**.
- **Strategic and implementation lessons learned** should be continually shared as they emerge.

- **This document will:**

- Provide **context** on the global epidemiological situation, discuss lessons learned from 2020 and clarify the focus of the report.
- Provide an **update on C19RM 2021 awards** and submissions made so far (countries, regions, breakdown by type of commodity and type of award).
- **Look ahead** to discuss our view on our priority areas for the next months and share some of the early impact.

- **These Monthly Reports to the Board will not:**

- Provide detailed information on specific countries as these will be reported through the Investment Committee Report to the Board.
- Maintain its format or type of data as the reports are improved and strengthened after feedback received from the Board.

Background and Context


Award Overview

Looking Ahead

COVID-19 Burden in regions we support

While daily cases in some countries are decreasing, models suggest infections far outnumber confirmed case numbers and there is concern of resurgence in many regions where the Global Fund has grants

COVID-19 Burden in regions the Global Fund supports




Key points

- Many countries that are **implementing Global Fund grants from the 2020-2022 allocation period have positivity rates above 5%**. These countries include Colombia, Mongolia, Namibia, Costa Rica, Bolivia, Malaysia, Iraq, Iran, Belarus, Zambia, Ecuador, Nepal and Bangladesh.
- Ten Global Fund implementing countries are also among the top 25 countries with the highest cumulative cases.** These are India, Russia, Colombia, Iran, Ukraine, Peru, Indonesia, South Africa, the Philippines and Iraq.
- Although not reflected in the data, a number of African countries are facing a resurgence of the pandemic that began to emerge in December. With **the emergence of new variants and evidence that true infections far outnumber confirmed cases, there are concerns of further increase in cases** for many African countries.
- Although at a regional level numbers in Southeast Asia are reducing, **India has seen very high numbers of cases and deaths with over 28 million recorded cases.**

SOURCE: TGF DASH data from WHO

Note that true infections far outnumber confirmed cases in many countries. See <https://ourworldindata.org/covid-models>

The increase in the number of people newly initiated on ART treatment is 6% lower than expected.




702,000 (+6%) more adults and children on ARTs by Q4 2020 relative to Q4 2019, compared with an expected increase of 12%.



69,000 (+8%) more adults and children on ARTs by the end of 2020 relative to end 2019, compared with an expected increase of 19.6%.

*Expected meaning: Assuming same level of performance in 2020 as 2019

Delivery of TB Services has also been significantly impacted: 27% fewer cases notified in Asia and 10% fewer cases notified in Africa in 2020 (compared to 2019)




0.5 million (-10%) fewer cases notified in 2020 relative to 2019; levels remain 20% lower in Q4/20 vs Q4/19
MDR-TB: 18% decline in number of people starting second line treatment; 1,600 fewer people treated
Sharp decline in Q2/20 and rate in Q4/20 is only 60% of levels achieved in Q4/19



1,2 million (-30%) fewer cases notified in 2020 relative to 2019
MDR-TB: 25% decline in number of people starting second line treatment; 23,000 fewer people treated
Sharp decline in Q2/20. Rate in Q4/20 remain 25% below level achieved in Q4/19

Based on data collected from countries with >85% of global disease burden.

Delivery of Malaria Services Significantly Impacted: 10-16% fewer malaria cases tested in 2020 (compared with 2019)



14.7 million (-10%) fewer cases tested in 2020 vs. 2019; levels recover to -5% by December 2020.
LLINs: 12 million (7%) fewer LLINs provided through continuous distribution; levels recover by December 2020.



The decline in suspected malaria cases tested is smaller in absolute terms but represents a larger proportion relative to the previous year: **1.4 million (-16%) fewer cases tested** in 2020 vs. 2019; levels remain -23% by December
LLINs: 1.8 million (18%) fewer LLINs were distributed through continuous distribution.

The COVID-19 Disruption Survey responses from 16 in-scope countries shows lowering levels of disruption versus earlier 2021

Level of disruption to services, products and in-country systems

Implementation Challenges

As of 1 May 2021

Trend from Jun 2020- May 2021

Group

Comment




Group	Comment
Community Service	Community-based service are still impacted, but there is clear improvement in disruption levels particularly in TB where disruption peaked in Jul 2020 .Service delivery risks are still moderate across geographies
Supply Chain	Targets were achieved in most instances for availability despite travel restrictions in-country as a result of covid-19 pandemic. Prevention, testing (HTS) and PLWHIV groups are still the most impacted. Reaching KPs has remained difficult as typical hotspots remain closed.
HIV	Highest financial disruptions in HIV but the overall trend is positive. Prevention, testing (HTS) and PLWHIV groups are still the most impacted. Reaching KPs has remained difficult as typical hotspots remain closed.
TB	Significant disruptions at the start of 2021 with active case finding impacted & significant concerns with oxygen supply. While there had been some improvements, particularly in service delivery have been made in the past month, risk levels in financial disruption and stock levels appear to be rising.
Malaria	The most cited disruptions in malaria programs were the inability to do large scale trainings, workshops, and other meetings. LLIN and other distribution campaigns remain largely unaffected with some slight delays, which indicates moderate to low risk levels

Note on meaning of Risk levels:
 For the National Stock question:
 • **Very High** means *Currently experiencing shortages*
 • **High** means *0-3 months supply remaining*
 For the In-country supply chain question:
 • **High** means *disruption impacting 25-50% of functional capacity*

Disruption Level: Low (Green), Moderate (Yellow), High (Orange), Very High (Red)

Risk Decrease (Downward arrow) / Risk Increase (Upward arrow)

In 2020 C19RM invested US\$759 million* to support countries fight COVID-19 and we intend to report on use of these funds when data becomes available.



- In 2020 the Global Fund approved US\$759 million for C19RM to support the COVID-19 response, which has funded:
 - \$243 million (32%) for mitigating COVID-19’s impact on HIV, TB and malaria programs;
 - \$442 million (58%) for reinforcing national COVID-19 responses; and
 - \$74 million (10%) for urgent improvements in health and community systems.
- The \$759 million included awards of \$182 million for COVID-19 diagnostics and \$276 million for Personal Protective Equipment (PPE)

- The target of approving all US\$759 million of Board-approved funds by 31 December 2020 was achieved successfully. This climbed above the initially allocated US\$500 million thanks to pledges from Germany, Canada, Denmark, Italy, Sweden, Norway and FIFA.
- We expect to be able to report on December 2020 PUDRs in the coming months, which are still coming in and being analyzed due to the flexibility offered.
- We expect absorption numbers on the 2020 approvals in last quarter of this year and will provide the information on use of funds when available.
- Unutilized funds from C19RM 2020 funds are being integrated into C19RM 2021 awards to ensure holistic management of C19RM funds.

Key features & enhancements of C19RM 2021, based on the improvement opportunities identified by the Board, OIG & the Secretariat (1/2)

Enhancements are focused on improving quality and effectiveness of the response mechanism and in- country impact

	Recommendations	Response
<p>Improved community Engagement</p>	<ul style="list-style-type: none"> • Ensure community buy in and engagement in funding requests • Ensure alignment with country strategies and coordination with existing in country investments 	<ul style="list-style-type: none"> ▪ 25% increase in CCM funding relative to annual budget ▪ Approved centrally managed funds to support communities engagement in C19RM funding requests ▪ Required engagement of national response coordinating bodies, communities, CSO
<p>Improved due diligence & monitoring & oversight</p>	<ul style="list-style-type: none"> • Increase transparency and robustness of reporting, monitoring and assurance • Funding request tools should allow for more systematic collection and robust reporting. 	<ul style="list-style-type: none"> ▪ Revised application package to ensure more systematic articulation of requests, transparent prioritization of investments, building on lessons; and identification of implementation risks ▪ M&E framework developed and being operationalized through an enhanced monitoring and oversight function ▪ End to end risk & control matrix & robust assurance developed
<p>GAC/CTAG support to ensure sustainable impact</p>	<ul style="list-style-type: none"> • Leverage internal and external expertise and technical guidance from partners with effective coordination • Focus on emergency needs while safeguarding the Fund’s investments in HIV, tuberculosis & malaria 	<ul style="list-style-type: none"> ▪ GAC/CTAG review support implemented for individual funding requests; Monthly GAC/CTAG review and update meetings ▪ Lessons learned sessions with GAC and CTAG

Key features & enhancements of C19RM 2021, based on the improvement opportunities identified by the board, OIG & the Secretariat (1/2)

Enhancements are focused on improving quality and effectiveness of the response mechanism and in- country impact

Recommendations

Optimizing speed and size of impact of funds

- Ensure **speed and agility** of the approval process
- Ensure **systematic approach to allow and encourage ambition through above allocation request**
- **Improving integration** of C19RM funding into grants, **maintaining flexibility** on allocations and **streamlining operational processes** to reduce transaction costs

Quality, technical rigor; OIG, Board Secretariat Lessons Learned

- Remaining **responsive to evolving technologies** on the market to help countries access the products they need.
- **Assess lessons learned during and post COVID-19 crisis and identify gaps.**

Response

- Created **multiple submission windows and fast-track can be submitted at any time** in line with individual country circumstances and programmatic needs.
- Designed fast track and full funding request modalities and offered **above allocation options.**
- Revised operational guidelines to streamline operations building on lessons learned; integrating **unutilized 2020 funds into 2021 awards** to ensure holistic management of C19RM funds.
- **Technical guidance in consultation with partners** to facilitate prioritizing of highest value interventions.
- **Maintained tight timelines** to ensure emergency responses come in, while allowing triage of more complex requests.
- **Frontloading integration to grant process where feasible,** allow reallocation of funding based on emergencies & exceptions for immediate order placements via wambo.org.
- **Upfront technical guidance & strengthened Secretariat review** with structured recommendations & management actions.

June Report Focus


This report focuses on flow of funds. As we move from awards into implementation, the focus will expand to provide visibility on flow of products and services in-country.

Our current reporting focus is on...

- A** Disease & HTM programmatic disruption Update
- B** C19RM Award
- C** Pipeline Update

...As we move into implementation we will be able to start reporting on...

- D** Flow of products
- E** Flow of services



Background and Context

Award Overview

Looking Ahead

C19RM Status of Awards Submissions and Pipeline




20% or US\$666 million of C19RM 2021 funding is awarded or recommended for Board Approval to 34 countries and 1 multicountry for a portfolio average of 8.3% of HTM allocation.

Full Funding requests: (1) US\$45 million was awarded to 4 applicants; (2) US\$127 million recommended for Board approval of award to 1 applicant.


Fast-track Funding Requests: US\$493 million was awarded.

Demand pipeline: 31% or US\$1,009 million is submitted or under review for potential C19RM 2021 funding (**US\$14 million** under Fast-track; **US\$333 million Base** and **US\$676 million Above Base** under Full Funding Request).

KPI: Notification letter KPI at 59% - 16 out of 27 Fast-Track Notification Letters sent within 7 business days. Remaining 11 NLs sent within 8 (7 NLs) and 9 (4 NLs) business days. Average of 7.3 business days. Full Review NL: 50% with 1 at 10 days and 1 at 12 days (11 average).




C19RM Overall Award: Submission Drill Down




20% of the current funding envelope is awarded or recommended for Board approval;
 Demand pipeline is robust in funding requests received/in process:

- Country demand is high with 32 of 45 submitted Full Funding requests above the 30% requested Base and Above Base Allocation.
- Unfunded demand of US\$340 million is registered from 3 countries.

Utilization of C19RM 2021



Awards/submission by region



Award (Fast track)
 Award (Full Review)
 Submitted Fast track
 Submitted Full review
 Balance to available funds

All values in the charts are in US\$ million and rounded.

For values in screening and under review only complete submissions are considered.

Values under Full Funding Review awards also include values recommended for board approval


C19RM Fast-track Drill Down

Note correction in remaining amount from version shared with the board on the 24th of June




- **US\$493 million is awarded** to 29 countries and 1 multicountry / via Fast-track (represents 6.8% of applicants' HTM allocation). This represents 55% of the total Fast-track mechanism.
- In total **39 fast-track requests were received, including 8 to be resubmitted due to incomplete documentation.**
- Assuming all under review are approved **44% of the US\$900 million ceiling remains available** for award.

Fast-track utilization



Award by region



Drill Down - Fast-track Requests Approved

US\$493 million awarded to date for a portfolio average of 6.8% HTM allocation, to 30 Fast-track Funding Requests. Final Submission to Notification Letter sent KPI of 7.3 business days average.

Country or Multicountry	Region	Fast-track Requested Amount (US\$)	Fast-track Approved Amount (US\$)	Fast-track Approved Amount (% of HTM Allocation)
Benin	Central Africa	8,180,868	8,180,868	7.9%
Burundi	Central Africa	1,336,336	1,336,336	1.1%
Togo	Central Africa	7,093,513	7,069,515	6.5%
Congo (Democratic Republic)	High Impact Africa 1	48,059,755	23,217,172	3.6%
Ghana	High Impact Africa 1	17,641,249	17,641,249	7.8%
Nigeria	High Impact Africa 1	66,281,259	50,083,594	5.6%
Ethiopia	High Impact Africa 2	33,482,083	30,683,553	6.9%
Kenya	High Impact Africa 2	31,148,545	31,148,545	7.5%
Mozambique	High Impact Africa 2	24,041,916	7,832,808	1.0%
Multicountry Southern Africa MOSASWA	High Impact Africa 2	292,072	254,235	4.2%
Tanzania (United Republic)	High Impact Africa 2	39,837,553	39,837,553	6.8%
Zambia	High Impact Africa 2	44,113,897	43,511,602	13.8%
Zimbabwe	High Impact Africa 2	37,126,648	37,126,648	7.4%
Cambodia	High Impact Asia	7,931,530	7,931,530	8.3%
India	High Impact Asia	75,000,000	75,000,000	15.0%
Indonesia	High Impact Asia	22,581,895	15,316,626	5.2%
Philippines	High Impact Asia	19,338,922	19,338,922	13.1%
Thailand	High Impact Asia	7,697,115	6,809,760	8.2%
Bolivia (Plurinational State)	Latin America and Caribbean	3,174,093	3,174,093	15.0%
Morocco	Middle East and North Africa	1,314,868	1,314,868	7.5%
Bhutan	South East Asia	530,224	530,224	15.0%
Nepal	South East Asia	5,098,263	5,098,263	9.9%
Papua New Guinea	South East Asia	5,838,485	5,784,985	7.4%
Solomon Islands	South East Asia	416,703	337,278	3.7%
Sri Lanka	South East Asia	1,414,093	1,414,093	15.0%
Timor-Leste	South East Asia	1,169,591	1,169,591	7.4%
Malawi	Southern and Eastern Africa	29,914,582	29,441,661	5.7%
Rwanda	Southern and Eastern Africa	11,329,802	11,329,802	6.0%
Gambia	Western Africa	4,973,480	3,682,162	8.5%
Senegal	Western Africa	7,190,918	7,174,661	9.3%
Total awarded		563,550,257	492,772,198	6.8%

Drill Down – C19RM Full Funding Requests Approved

Note the breakdown shared with the board on the 24th of June is slightly more detailed

US\$173 million awarded, including funding recommended for Board approval

Full funding investments are still mainly **directed towards reinforcing COVID-19 national response** but present a more balanced picture across the priority areas than with Fast-track requests.

Country or Multicountry	Mitigate COVID-19 impact on HIV, TB and malaria programs		Reinforce COVID-19 national response		Urgent improvement to health and community systems				Total
					Community, Rights and Gender		RSSH Investments		
	Amount (US\$)	%	Amount (US\$)	%	Amount (US\$)	%	Amount (US\$)	%	
Kyrgyzstan	538,845	8.2%	4,793,102	72.5%	165,992	2.5%	1,111,159	16.8%	6,609,097
Uganda	10,584,560	8.3%	92,740,167	73.1%	5,327,156	4.2%	18,210,610	14.4%	126,862,493
Peru	5,819,358	39.0%	7,926,975	53.1%	1,191,550	8.0%	-	0.0%	14,937,883
Angola	2,173,149	10.5%	18,338,111	88.8%	56,941	0.3%	81,884	0.4%	20,650,086
Mongolia	1,685,776	40.4%	1,755,455	42.1%	729,315	17.5%	-	0.0%	4,170,546
Total awarded	20,801,689	12.0%	125,553,809	72.5%	7,470,954	4.3%	19,403,653	11.2%	173,230,105


*Subject to Investment Committee recommendation for final Board approval

C19RM Award by Priority Area



Award by priority area: Investments are mainly directed towards reinforcing COVID-19 national response. This is expected as the initial awards are for Fast-track. With only five Full Funding Requests awarded or recommended for Board approval, we are already seeing a more balanced picture across the priority areas.

C19RM Awards by Priority Area



All values in the charts are in US\$ million and rounded. Program management costs are included in Reinforce
 Values above include Fast-track awards and Full Funding Requests awarded and/ or recommended for Board approval


C19RM Award by WHO Pillars

Note correction in pillar amounts from version shared with the board on the 24th of June



C19RM investments are primarily directed towards **Pillar 5: National laboratories (27%)**, **Pillar 6: Infection prevention and control (29%)** and **Pillar 7: Case management (36%)**. The remaining investments are primarily split among and **Pillar 9: Maintaining essential health services and systems (4%)**.

C19RM Awards by WHO Pillar



All values in the charts are in USD million and rounded

Values above include Fast track awards, Full funding requests awarded and/ or recommended for board approval

Differences in values between Global Fund defined health products are accounted for by a more limited set of products that are included under these categories


C19RM Award by Health Products



Health product investments are more balanced across key Health Products

Around **60%** of awards to date are expected to use **Wambo** as the procurement channel.

C19RM Awards by type



All values in the charts are in USD million and rounded

Values above include Fast track awards, Full funding requests awarded and/ or recommended for board approval

Differences in values between Global Fund defined health products are accounted for by a more limited set of products that are included under these categories

Health Product Demand Reporting

Looking Ahead: Supply Largely Unconstrained

Health Product Demand

Diagnostics

- **Automated PCR tests:** Continued modest demand received for high-volume platforms.
 - **Manual PCR tests:** Compared to 2020, modest increase in demand observed¹.
 - **Antigen RDTs:** Lower than anticipated demand despite reduced pricing.
 - ➔ *Global Fund is working with countries and regional networks, such as ASLM and AFRO, to support uptake efforts, including finalization of testing strategies.*
- WHO will soon release updated guidelines on testing which may reshape demand.

IPC

- **PPE:** Modest demand received in Fast-track Funding Requests.

Case Management

- **Therapeutics:** Increasing requests for dexamethasone and heparin to support severe cases of COVID-19.
- **Oxygen therapy:** Significant demand for oxygen consumables and equipment, including medium to long term investments in PSA plants.

Health Product Sourcing and Supply

- **Largely unconstrained supply** for diagnostics and IPC/PPE with reasonable levels of inventory available.
- Strategic and mainstream **diagnostics** and **IPC** health products will mainly be procured **through PPM/wambo**. Selected products (e.g., disinfectants) recommended for local procurement.
- **Improved pricing** on diagnostics and PPE products, with reductions of up to 30% since Q1 2021:

US\$2.50 - \$3

Average pricing on Ag RDTs. (prev. US\$5)

US\$10 per test

Automated PCR tests for the high-volume platforms (prev. US\$19)



PPE prices were reduced significantly since Q3 2020 (e.g., nearly 90% reduction on medical masks and N95/FPP2 respirators)

- Constraints in delivery relate more to logistics capacity and timely importation clearance.

- No supply constraints for repurposed therapeutics.
- Global supply constraints for oxygen-related products linked to surge in demand.
- Ongoing collaboration with partners and Oxygen Task Force to address supply capacity challenges, including for liquid oxygen.

¹ From countries that requested Global Fund financing.

Background and Context

Award Overview

Looking Ahead


C19RM Fast-track Actuals & Projections




44 Fast-track Funding Request are awarded, submitted or projected to be submitted for US\$572 million (based on amounts awarded, submitted and HTM allocation projections).

39 Fast-track Funding Requests approved/received so far for US\$553 million for an average 6.7% of HTM allocation.

Actuals and projections # of FR



Actuals and Projection \$ million Actuals




C19RM Full Review Projection




126 or 98% of applicants have indicated interest in applying for C19RM funds.
 Funding amount projected to be submitted is US\$ 3,856 million (including Fast-track amounts).
 There have been significant shifts to later windows as applicants finalize their Full Funding Requests.
Note US\$ projected amounts based on 30% HTM allocation, in line with assumptions in Allocation Letter.

Projection # of FR



Projection \$ million



*Projections are based on number of applicants registered

As we prepare for more full funding requests, we are already identifying Emerging Lessons Learned from C19RM 2021

What is working well...

Review of Fast-track Funding Requests

- **Effective CTAG and GAC Partner reviews of Fast-track funding requests:**
 - The newly set up Partnership Engagement Platform allows all reviewers to see comments provided and engage in discussion, including through structured review form and discussion boards.
 - **Strong engagement with timely input:** comments inform CT reviews and Investment Committee decisions. Average of 10 reviewers for each Fast-track funding request.
- **Strong alignment with NSPRPs and improved coordination with national COVID-19 response bodies** – majority of reviewers rate “strongly agree” or “agree”. Evidence of endorsement is provided as part of screening.
- **Overall strong alignment with WHO guidelines (reporting on Pillars) and upfront technical guidance provided by the Global Fund** – based on outcome of Secretariat, CTAG/GAC reviews; activities outside scope are removed; key issues mainly in IPC/PPE, Testing Strategies and Therapeutics – communicated in Notification Letters.

Review Process and Investment Decision-Making

- **Strengthened quality of internal review process with structured recommendations, management actions and conditions to award as needed**, including on health product management, procurement channels, and others. Issues communicated in Notification Letters; to be monitored, with management oversight by IC.
- **Maintained speed and agility of review process, building on success of C19RM phase 1.** Notification Letters sent on average within 7.3 business days from the start of the Fast-track review process.

As we prepare for more full funding requests, we are already identifying Emerging Lessons Learned from C19RM 2021 (continued)

Challenges faced...

Screening Issues

- Challenges in receiving complete application packages and timely review inputs.
- HPMT and Budget inconsistencies and lack of clarification of proposed implementation arrangements.
- In some cases, significant proportion missing CCM signatures.
- Secretariat learning curve in adapting to refined C19RM business processes.

Technical Issues

- Oxygen operational plans and specifications
- Testing strategies: use of Ag RDTs in community settings testing by CHW and at Ports of Entry
- PPE guidelines – non-COVID-19 PPE

Other emerging issues we expect to continue to monitor/address as reporting continues

- Managing trade-off between speed and quality of funding requests and ensuring **due diligence***
- Relative prioritization of investments across reinforcing COVID-19 response, HTM mitigation and urgent strengthening of health systems

There are 3 pillars to the C19RM review & due diligence process

- 1 Secretariat review: Country Teams, with due diligence validated independently by cross-functional teams**
- **Country Teams** on overall request, prioritization & expected outcomes, coordination of investments, implementation, associated risks & mitigation measures
 - **TAP** on epidemiological & HTM mitigation analysis, technical soundness & investment prioritization & expected outcomes
 - **Supply Operations & Health Product Managers** focusing on COVID-19 products
 - **Risk** on assurance & mitigation measures
 - **Finance** review of budgets and absorption
 - **Health Finance** on coordination of investments, including domestic resources, value for money
 - **CRG** on community intervention investments with a focus on GBV, community & civil society engagement
 - **CRG, CCM Hub & C19RM Secretariat** eligibility screening, CCM endorsement, key populations/communities & civil society engagement

- 2 GAC/CTAG partners: follow a set of questions to guide their reviews including:**
- Alignment with **NSPRP, WHO** guidance & **national coordination bodies**
 - **Technical rigor of proposed investments** in “pure COVID-19” response (including Dx/PCR, Ag RDTs, PPE & O2), HTM mitigation, health systems & CRG; including on longer-term outcomes & pandemic preparedness pathways
 - **Coordination of investments** with other donors & partners

- 3 Investment Committee: conducts final review, taking into consideration Secretariat as well as GAC/CTAG partner inputs and recommendations**
- **Uses a set of questions to guide its review** e.g., *what are we funding, what has been prioritized / recommended for funding & why (how it fits into national strategies), what are expected outcomes? What are the implementation and delivery mechanisms; What are associated risks & mitigations? What procurement channels proposed, & ensure alignment with policy to ensure value for money and safeguards? What will we not fund – based on due diligence review & partner inputs? Coordination of investments?*
 - **Of US\$1,078m submitted, US\$666m, is approved, US\$340m is unfunded demand & US\$72m is not approved** either due to misalignment with WHO guidance, not a priority for C19RM / Fast-track, investment rationale, efficiencies, not value for money

We have strengthened each of the pillars and continue to look for ways to improve quality while maintaining urgency

Actions taken to improve....

Secretariat review: *is more comprehensive and collaborative*

- **Screening has been improved** through training and communications of CTs
- **Screening checklist** shared with CCM & Country Teams.
- Detailed **step-by-step guide** developed for screening, review and approval process
- **Significant follow-up and several times daily back-and-forth between CT and CCM, MoH, PRs & in-country partners** during the reviews; getting to better understanding and rationale on main asks in the FRs; assessing and deeper-dives on red-flags, key questions, as well as priority areas arising from CT, reviewers in other teams, & GAC/CTAG inputs

GAC/CTAG partners: have increased visibility

- Inputs from GAC & CTAG partners come from **both the review survey and discussion boards**
- Inputs are summarized and **shared with the CT for response**
- GAC CTAG **monthly reports & Lessons learned sessions**
- **Regular operational updates and updates to Technical Guidelines** to address emerging issues regularly updated on the Fund website


Investment Committee has more robust inputs for decision making

- We now have **pre-IC meetings for high impact and core full funding request** to discuss and highlight most salient issues for the IC discussion
- Experience on one funding request led to **engagement of support from a CTAG partner to rapidly develop a tool enabling standardized**, comparative technical and operational assessment of requests for Oxygen support that is now applied to all C19RM requests. This tool has also been shared with CCMs and CTs for use in development of FRs, where appropriate.
- Emerging issues highlighted for GAC/CTAG engagement and updates to technical guidance
 - Design of **Monitoring and Oversight mechanism**

CTAG/GAC comments have been extremely valuable for our due diligence and inform IC decision making. Building quality funding requests is our priority as we continue to refine our approach, we expect approvals and implementation will go faster.




Upcoming Reports will contain more data

As we move into implementation, data on financials, products, services and programmatic performance will become available & be included in these reports



- Indicators**
 - FR pipeline
 - Funds approved and committed
 - Investment in Board categories, interventions and pillars
 - Unfunded demand
- Financial**
 - Disbursement forecast
 - Actual disbursement
 - Expenditure
- Health products**
 - Order placement
 - In-country central delivery
 - Delivery at facility / testing site level
 - On-shelf availability
- Services**
 - Service availability: testing & oxygen therapy
 - Service disruption at health facility and community sites
 - Implementation progress (PR evaluation)
- Programmatic**
 - Tracer indicators for HTM
 - Programmatic performance at country and portfolio level

Illustrative – mock-ups





Early success | We remain committed to the people we serve and are encouraged by the progress made in countries like **The Gambia**, who received the first C19RM 2021 award.


Context

- The COVID-19 outbreak continues to pose a significant public health problem to The Gambia with over **6000 confirmed cases** presenting challenges to the country's already fragile health system
- In response to the pandemic in partnership with the United Nations Risk Communication and Community Engagement (UNRCCE), the country has developed a strategic response.
- The Multi-Disciplinary Facilitation Teams (MDFTs) members **trained 4170 Village Development Committees (VDCs)**, Over 240 Alkalos (Gambian village chiefs), **150 Community Based Organizations (CBOs)** and **30 Community Volunteers (CV)** were trained on the safety and efficacy of COVID-19 vaccines. **150 traditional healers and 90 religious' leaders were sensitized** about COVID-19

C19RM Response

- The Fast-track request from the Gambia was the first request the IC **approved US\$3,682,162 out of the early submissions, on May 11th**
- The focus of the request was on laboratory infrastructure, medical equipment & therapeutics **with a focus on affected communities**
- The Fast-track Funding Request was **endorsed by all CCM members as well as by the national COVID-19 response coordinating body**, which supports the RCCE interventions
- **Key stakeholders were involved** including MOH, various national partners, and Civil Society constituencies and the **CCM put in place a multi-sectorial national task force to ensure a transparent process**

The investment committee awarded \$ 3.7 USD million



Going forward

- About 12 GAC and CTAG reviewers, **reviewed and supported the Gambia's funding request**
- We expect the **health products to complement the existing community engagement efforts** and anticipate the Gambia's Full funding request





Early success

We remain committed to the people we serve and are encouraged by the progress made in countries like **Senegal** where there has been strong stakeholder engagement in funding request development.


Context Following cumulative confirmed cases of over 40000, Senegal submitted a funding request for emergency procurement of COVID-19 health products. The interventions in the request **contribute to the outcomes of the country's Strategic Preparedness and Response Plan**, expected to be finalized by the end of July. The development of the fast-track funding request involved the COVID 19 task force in the Country.

- Country Response with C19RM**
- CCM fast-track request of Euros 6.5m including 1.9 for PPE, 0.7m for O2 and 1.6 for PSM costs, was fully endorsed by Civil Society CCM representatives
 - The products were **selected based on a COVID-19 tools (PPE) national quantification which includes Community Based Organizations' (CBO) needs**, to ensure continuity of HTM services delivery by CBOs and 66% of the masks requested being for the CBO's
 - **Two Civil Society stakeholders are recipients** of C19RM 2021 funds

Robust engagement process

- A proper country dialogue coordinated by the CCM and the National Epidemics Response Committee, with **9 working groups including one on Gender and Human Rights and one on Civil Society needs**
- A CCM **multisectoral writing committee made of National HTM Programs, National Drug Store, Laboratories, treatment centers and Civil Society** (key and affected populations including those mostly affected by COVID-19 as recommended by the C19RM guidelines)
- Use of **virtual consultations to engage with communities** organized by CCM Civil Society Monitoring Committee (in place since NFM3 grant making)
- Use of **Technical Assistance to support the writing of the request**, to conduct the situational analysis and quantification of Civil Society and CBOs needs in PPE

Award of – EUR 6,504,906 on 16 May 2021



- Going Forward**
- The request is **evidence of the power of communities**. One reviewer said that they were “very glad to see detailed quantification of PPE/IPC needs for malaria community-based and campaign activities”
 - Going forward **CSO engagement will continue to be part of eligibility criteria**, and the Secretariat will also encourage CSO engagement through long term partnerships/ across PRs as done in Kenya



Thank you

